Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade

Michael V. Fiandalo, John J. Stocking, Elena Pop, John H. Wilton, Krystin Mantione, Yun Li, Kristopher Attwood, Gissou Azabdaftari, Yue Wu, David S. Watt, Elizabeth M. Wilson, James L. MohlerOncotarget 2018 · DOI

TL;DR

This study investigates how prostate cancer (CaP) develops resistance to androgen deprivation therapy (ADT) by exploring the "backdoor" pathway of dihydrotestosterone (DHT) synthesis. The researchers found that inhibiting both the "frontdoor" (via dutasteride) and the backdoor pathways (using enzyme mutants) significantly reduces DHT levels in CaP cells, offering a promising new therapeutic strategy to combat castration-resistant prostate cancer (CRPC).

What Problem Does This Paper Address?

Androgen deprivation therapy (ADT) is a standard treatment for advanced prostate cancer, aiming to starve cancer cells of androgens like testosterone (T) and dihydrotestosterone (DHT), which fuel their growth. However, a major challenge is that CaP often becomes resistant to ADT, developing into castration-recurrent/resistant prostate cancer (CRPC). One key mechanism contributing to this resistance is the cancer cells' ability to synthesize DHT intratumorally through alternative pathways, even when circulating androgen levels are low.

The "frontdoor" pathway involves the conversion of T to DHT. The "backdoor" pathways, however, bypass T altogether. Specifically, the "primary backdoor pathway" converts 5α-androstane-3α,17β-diol (DIOL) to DHT using a family of enzymes called 3α-oxidoreductases. The problem is that there are four such enzymes, and they are redundant, meaning inhibiting just one might not be enough. Existing treatments like dutasteride (a 5α-reductase inhibitor) target the frontdoor pathway but are not fully effective against CRPC, suggesting that blocking the backdoor pathway is crucial. This paper aims to determine if inhibiting these 3α-oxidoreductases can effectively reduce DHT synthesis and overcome resistance.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics: They used the COBALT tool to align protein sequences of the four 3α-oxidoreductases (HSD17B6, RDH16, DHRS9, and RDH5) to identify conserved catalytic sites.
  • Immunohistochemistry (IHC): They examined tissue samples from patients to assess the expression levels of these four enzymes in benign prostate tissue, prostate cancer tissue, and CRPC tissue.
  • Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR): This technique was used to measure the mRNA levels of the 3α-oxidoreductases, 5α-reductases (SRD5A), and androgen receptor (AR) in various CaP cell lines and xenografts.
  • Site-Directed Mutagenesis: They created catalytically inactive mutants of the 3α-oxidoreductases by altering key amino acid residues (specifically tyrosine and lysine) known to be essential for their function.
  • Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): This was the primary analytical tool used to quantify androgen levels (T, DHT, DHEA, ASD, AND, and 5α-dione) in cell culture media and cell pellets.
  • Cell Culture Experiments: They used CaP cell lines (LAPC-4, VCaP, C4-2, CWR-R1) and CV-1 cells, transfecting them with plasmids encoding either wild-type or mutant 3α-oxidoreductases. These cells were then treated with various androgen precursors or inhibitors.
  • Western Blotting: Used to confirm the successful expression of the transfected enzymes in the cells.

Datasets

The study utilized several datasets:

  • Human Prostate Tissue Samples: Tissue microarrays (TMAs) from 72 patients (benign prostate, AS-CaP, CRPC) were used for IHC analysis. Additional TMAs were from a clinical trial involving finasteride treatment.
  • Prostate Cancer Cell Lines: LAPC-4, LNCaP, C4-2, PC-3, DU145, and VCaP cell lines were used.
  • Prostate Cancer Xenografts: CWR22 (androgen-dependent) and rCWR22 (ADT-recurrent) xenografts were used.
  • Clinical Trial Data: Data from a randomized, double-blind, placebo-controlled clinical trial of selenium supplementation and finasteride treatment (Selenium and Finasteride Pre-Treatment Trial, I104607) was used to analyze tissue samples from subjects treated with finasteride.

No new benchmarks were introduced; the study focused on analyzing existing biological systems and patient samples.

Key Insights and Ideas

  • Conserved Catalytic Site: All four 3α-oxidoreductases share a common catalytic site, suggesting a unified target for inhibition.
  • Expression in Clinical Samples: These enzymes are expressed in actual human prostate tissues, including benign, cancerous, and castration-resistant forms, highlighting their clinical relevance.
  • Cell Line Specificity: The activity of specific 3α-oxidoreductases can vary between different cell lines, underscoring the complexity of androgen metabolism.
  • Catalytic Residues are Crucial: Specific tyrosine and lysine residues are essential for the enzymatic activity of these enzymes, providing targets for creating inactive mutants.
  • Combined Blockade is Superior: Inhibiting both the frontdoor (SRD5A) and backdoor (3α-oxidoreductases) pathways simultaneously is significantly more effective at reducing DHT than targeting either pathway alone.

Key Results

  • 3α-oxidoreductases are expressed in CaP: IHC confirmed the presence of HSD17B6, RDH16, DHRS9, and RDH5 in benign and cancerous prostate tissues, with some showing increased nuclear expression in CRPC.
  • Mutant enzymes reduce DHT: Transfecting CaP cells with catalytically inactive mutants of 3α-oxidoreductases (e.g., RDH16-Y176F,K180R) significantly reduced DHT levels compared to cells expressing wild-type enzymes.
  • Combined therapy is potent: In LAPC-4 cells, the combination of dutasteride (frontdoor inhibitor) and RDH16 mutants (backdoor inhibitor) led to a greater decrease in DHT levels than dutasteride alone. This effect was also observed in VCaP and C4-2 cells.
  • Finasteride doesn't fully suppress DHT: Analysis of tissues from subjects treated with finasteride showed that while DHT levels were decreased, they remained sufficient to activate the androgen receptor, suggesting backdoor pathways are still active.

Limitations and Future Work

  • Transient Expression: The study relied on transient expression of 3α-oxidoreductases in CaP cell lines due to low endogenous expression. This can lead to variability in expression levels between cells.
  • Cell Line Specificity: The observed activity of specific 3α-oxidoreductases varied across cell lines, suggesting that a universal approach might require targeting all four enzymes.
  • Limited Androgen Measurement: The LC-MS/MS method was limited to measuring six specific androgens, excluding potentially active metabolites like glucuronidated or sulfated forms. DIOL itself was also difficult to measure directly.
  • Short-Term Inhibition: The observed effects of combined blockade were measured over a 12-hour period. Clinical effectiveness would require longer-term studies.

The authors suggest that developing effective inhibitors for the four 3α-oxidoreductases is a critical next step. A combined therapeutic strategy targeting both the frontdoor and backdoor pathways holds promise for significantly reducing intratumoral DHT, potentially overcoming resistance to current ADT and improving outcomes for men with advanced CaP.

Summary updated

Abstract

Androgen deprivation therapy (ADT) is palliative and prostate cancer (CaP) recurs as lethal castration-recurrent/resistant CaP (CRPC). One mechanism that provides CaP resistance to ADT is primary backdoor androgen metabolism, which uses up to four 3α-oxidoreductases to convert 5α-androstane-3α,17β-diol (DIOL) to dihydrotestosterone (DHT). The goal was to determine whether inhibition of 3α-oxidoreductase activity decreased conversion of DIOL to DHT. Protein sequence analysis showed that the four 3α-oxidoreductases have identical catalytic amino acid residues. Mass spectrometry data showed combined treatment using catalytically inactive 3α-oxidoreductase mutants and the 5α-reductase inhibitor, dutasteride, decreased DHT levels in CaP cells better than dutasteride alone. Combined blockade of frontdoor and backdoor pathways of DHT synthesis provides a therapeutic strategy to inhibit CRPC development and growth.
BibTeX
@inproceedings{fiandalo2018inhibition,
  author = {Michael V. Fiandalo and John J. Stocking and Elena Pop and John H. Wilton and Krystin Mantione and Yun Li and Kristopher Attwood and Gissou Azabdaftari and Yue Wu and David S. Watt and Elizabeth M. Wilson and James L. Mohler},
  title = {{Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade}},
  booktitle = {Oncotarget},
  year = {2018},
  doi = {10.18632/oncotarget.24107},
}
Figure